GLP-1 Market Drives Specialty Pipeline Expansion

Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumGlucagon-like peptide-1 (GLP-1) medications for the management of obesity and type 2 diabetes will continue to dominate the specialty pipeline in 2026, including oral options, novel targets, and dual agents.GLP-1 product sales hit approximately $132 billion in 2025, said Dan Powell, PharmD, the patient solutions manager and pharmacist-in-charge of the Walgreens Gene and Cell Services Pharmacy, in Pittsburgh,